Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

The Finviz API: Higher Limits, Clearer Data, and More Ways to Connect

Get Started Now

Immunovant Inc.

Contributing Author

Recent Articles by Immunovant Inc.

Sep-23	Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus IMVT -7.37% GlobeNewswire
Aug-06	Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 IMVT GlobeNewswire
Jul-23	Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 IMVT GlobeNewswire
May-20	Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 IMVT +35.26% GlobeNewswire
May-11	Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026 IMVT GlobeNewswire
Apr-02	Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) IMVT GlobeNewswire
Feb-06	Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 IMVT +12.43% GlobeNewswire
Jan-23	Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 IMVT GlobeNewswire
Dec-11	Immunovant Announces Pricing of $550 Million Common Stock Financing IMVT +5.31% GlobeNewswire
Nov-10	Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025 IMVT GlobeNewswire
Oct-27	Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 IMVT +13.15% GlobeNewswire
Sep-03	Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients IMVT +10.82% GlobeNewswire
Aug-11	Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025 IMVT GlobeNewswire
May-29	Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 IMVT +5.60% GlobeNewswire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)